Universe Pharmaceuticals (NASDAQ:UPC) Upgraded at Wall Street Zen

Wall Street Zen upgraded shares of Universe Pharmaceuticals (NASDAQ:UPC) to a hold rating in a research note issued to investors on Saturday,Wall Street Zen reports.

Separately, Weiss Ratings raised shares of Universe Pharmaceuticals from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Wednesday, July 29th. One research analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, the company has an average rating of “Sell”.

Universe Pharmaceuticals Stock Performance

UPC opened at $4.58 on Friday. The company has a debt-to-equity ratio of 0.04, a quick ratio of 3.90 and a current ratio of 4.05. The business has a 50-day moving average of $5.11 and a two-hundred day moving average of $3.68. Universe Pharmaceuticals has a 12 month low of $2.00 and a 12 month high of $17.96.

Universe Pharmaceuticals (NASDAQ:UPC) last announced its quarterly earnings data on Wednesday, July 29th. The company reported ($1.38) earnings per share for the quarter. The firm had revenue of $4.52 million for the quarter.

About Universe Pharmaceuticals

Universe Pharmaceuticals, Inc is a clinical‐stage biotechnology company focused on the discovery and development of novel therapeutics for ocular diseases. The company’s primary research efforts center on small-molecule compounds designed to address unmet needs in glaucoma, ocular hypertension and post-surgical ocular inflammation. By leveraging targeted enzyme inhibition and proprietary formulation technologies, Universe aims to bring forward topically administered medications that combine efficacy with an improved safety profile versus existing treatments.

The company’s lead candidate, UPC-1001, has been advanced into clinical trials for the treatment of open-angle glaucoma and ocular hypertension, where it seeks to lower intraocular pressure through a unique mechanism of action.